Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drainage and antibiotics in laparoscopic right hemicolectomy
NCT04977882Phase 1Completed
- Sponsor
- University of Rome Tor Vergata
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ceftriaxone and metronidazole in colon cancer, sponsored by University of Rome Tor Vergata. Primary endpoint: Tolerance to solid diet at 30 days. Started Oct 2020; status: completed.
02
Drugs
ceftriaxonemetronidazole
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04977882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977882.